Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer

KRAS is one of the driver oncogenes in non-small-cell lung cancer (NSCLC) but remains refractory to current modalities of targeted pathway inhibition, which include inhibiting downstream kinase MEK to circumvent KRAS activation. Here, we show that pulsatile, rather than continuous, treatment with ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Hyejin, Deng, Jiehui, Li, Shuai, Silk, Tarik, Dong, Lauren, Brea, Elliott J., Houghton, Sean, Redmond, David, Zhong, Hong, Boiarsky, Jonathan, Akbay, Esra A., Smith, Paul D., Merghoub, Taha, Wong, Kwok-Kin, Wolchok, Jedd D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719696/
https://www.ncbi.nlm.nih.gov/pubmed/30995478
http://dx.doi.org/10.1016/j.celrep.2019.03.066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719696/
https://www.ncbi.nlm.nih.gov/pubmed/30995478
http://dx.doi.org/10.1016/j.celrep.2019.03.066

Ejemplares similares